Guardant Health’s blood-based colorectal cancer screening test, Shield, has been named a winner of Fast Company’s 2025 World Changing Ideas Awards. Shield is the first FDA-approved blood test for primary CRC screening, offering a convenient alternative to colonoscopy and stool tests, which 1 in 3 eligible U.S. adults avoid.
The test detects early-stage cancer with a simple blood draw during a routine visit, aiming to improve early detection and save lives. Shield has also been recognized by TIME and Popular Science, and was recently included in NCCN’s updated CRC screening guidelines.